Agnieszka Boesen

Array ( [id] => 9383446 [patent_doc_number] => 20140086927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-27 [patent_title] => 'NOVEL EPITOPE AND MECHANISM OF ANTIGEN-ANTIBODY INTERACTION IN AN INFLUENZA VIRUS' [patent_app_type] => utility [patent_app_number] => 14/035495 [patent_app_country] => US [patent_app_date] => 2013-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 51147 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14035495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10353625 [patent_doc_number] => 20150238630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'Compositions and Methods for Antigen Targeting to CD180' [patent_app_type] => utility [patent_app_number] => 14/426635 [patent_app_country] => US [patent_app_date] => 2013-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 17118 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14426635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9192233 [patent_doc_number] => 20130331548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-12-12 [patent_title] => 'COMPOSITIONS OF FLAGELLIN AND PAPILLOMAVIRUS ANTIGENS' [patent_app_type] => utility [patent_app_number] => 13/971203 [patent_app_country] => US [patent_app_date] => 2013-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 22237 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13971203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9895118 [patent_doc_number] => 20150050317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'Means for Eliciting an Immune Response and a Method Therefor' [patent_app_type] => utility [patent_app_number] => 13/969862 [patent_app_country] => US [patent_app_date] => 2013-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9102 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13969862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10318537 [patent_doc_number] => 20150203540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-23 [patent_title] => 'Cytoplasmic Tail Modifications to Boost Surface Expression and Immunogenicity of Envelope Glycoproteins' [patent_app_type] => utility [patent_app_number] => 14/417228 [patent_app_country] => US [patent_app_date] => 2013-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 25134 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14417228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10289239 [patent_doc_number] => 20150174237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'MULTIMERIC FUSION PROTEIN VACCINE AND IMMUNOTHERAPEUTIC' [patent_app_type] => utility [patent_app_number] => 14/416780 [patent_app_country] => US [patent_app_date] => 2013-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 22029 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14416780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9771227 [patent_doc_number] => 20140294890 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-02 [patent_title] => 'Recombinant Adenovirus Vaccines' [patent_app_type] => utility [patent_app_number] => 13/946633 [patent_app_country] => US [patent_app_date] => 2013-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9041 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13946633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11780069 [patent_doc_number] => 09389229 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-07-12 [patent_title] => 'Methods for detecting and measuring aggregation' [patent_app_type] => utility [patent_app_number] => 13/944857 [patent_app_country] => US [patent_app_date] => 2013-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 23 [patent_no_of_words] => 23749 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13944857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10306530 [patent_doc_number] => 20150191530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'HUMAN MONOCLONAL ANTIBODY AGAINST THE VP1 PROTEIN OF JC VIRUS' [patent_app_type] => utility [patent_app_number] => 14/410896 [patent_app_country] => US [patent_app_date] => 2013-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 8034 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14410896 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10290684 [patent_doc_number] => 20150175683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'BINDING MOLECULES TARGETING PATHOGENS' [patent_app_type] => utility [patent_app_number] => 14/411017 [patent_app_country] => US [patent_app_date] => 2013-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13585 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14411017 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10305481 [patent_doc_number] => 20150190481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-09 [patent_title] => 'COMBINATION FOR TREATING AN INFLAMMATORY DISORDER' [patent_app_type] => utility [patent_app_number] => 14/411047 [patent_app_country] => US [patent_app_date] => 2013-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 33619 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14411047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10365858 [patent_doc_number] => 20150250864 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-10 [patent_title] => 'ANTI-CANCER VACCINES' [patent_app_type] => utility [patent_app_number] => 14/410025 [patent_app_country] => US [patent_app_date] => 2013-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 25761 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 25 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14410025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11880755 [patent_doc_number] => 09751914 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-05 [patent_title] => 'Polypeptides and antibodies for treating HBV infection and related diseases' [patent_app_type] => utility [patent_app_number] => 14/406940 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 17 [patent_no_of_words] => 20935 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 208 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14406940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12145086 [patent_doc_number] => 09879329 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-01-30 [patent_title] => 'Method for evaluation of viability of viruses with lymphotropism properties' [patent_app_type] => utility [patent_app_number] => 14/397680 [patent_app_country] => US [patent_app_date] => 2013-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5001 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 212 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14397680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9160970 [patent_doc_number] => 20130309248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/897843 [patent_app_country] => US [patent_app_date] => 2013-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 39933 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9160970 [patent_doc_number] => 20130309248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-21 [patent_title] => 'HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H3N2 AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/897843 [patent_app_country] => US [patent_app_date] => 2013-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 39933 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10282109 [patent_doc_number] => 20150167106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'NUCLEIC ACID MOLECULE THAT BINDS TO INFLUENZA VIRUSES AND USE THEREOF' [patent_app_type] => utility [patent_app_number] => 14/405026 [patent_app_country] => US [patent_app_date] => 2013-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 15367 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11282691 [patent_doc_number] => 09498529 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor' [patent_app_type] => utility [patent_app_number] => 13/862497 [patent_app_country] => US [patent_app_date] => 2013-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 8826 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13862497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9930931 [patent_doc_number] => 20150079123 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-19 [patent_title] => 'LIVE, ATTENUATED RUBELLA VECTOR TO EXPRESS VACCINE ANTIGENS' [patent_app_type] => utility [patent_app_number] => 14/387514 [patent_app_country] => US [patent_app_date] => 2013-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 45815 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14387514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864229 [patent_doc_number] => 20150044248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'POLYPEPTIDES AND THEIR USE IN TREATING METAPNEUMOVIRUS (MPV) INFECTION' [patent_app_type] => utility [patent_app_number] => 14/390894 [patent_app_country] => US [patent_app_date] => 2013-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11191 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390894 [rel_patent_id] =>[rel_patent_doc_number] =>)